LLY

Hims & Hers Health has expanded its platform to allow clinicians to prescribe Eli Lilly GLP-1 treatments (Zepbound vials, KwikPen, and Foundayo) fulfilled via LillyDirect, while also broadening access to Novo Nordisk therapies. The company additionally acquired a facility to strengthen peptide capabilities ahead of an FDA review on compounding. These moves deepen HIMS's role in prescription weight management and could materially shift its product mix.

AI-generated content for informational purposes only. Not investment advice.

Eli Lilly's new oral GLP-1 weight-loss drug is reportedly seeing prescription volumes trail Novo Nordisk's oral Wegovy. JPMorgan has initiated coverage on Hims & Hers Health. Regeneron is offering a new hearing-loss therapy at no cost.

AI-generated content for informational purposes only. Not investment advice.

Spherix Global Insights released a report finding high adoption rates among physicians for both Eli Lilly's LillyDirect and Novo Nordisk's NovoCare direct-to-patient platforms for obesity treatment, though workflow differences are driving a specialty-based split in platform preference. LillyDirect launched in January 2024 and NovoCare in March 2025, with both now increasingly integrated into physician workflows. The report highlights evolving competitive dynamics in the direct-to-patient obesity drug distribution channel.

AI-generated content for informational purposes only. Not investment advice.

Eli Lilly's stock declined after data showed Novo Nordisk's oral Wegovy outperforming Lilly's newly launched weight-loss pill, Foundayo. The comparison highlights intensifying competition in the oral GLP-1 weight-loss drug market. Both companies are vying for market share in the rapidly growing obesity treatment segment.

AI-generated content for informational purposes only. Not investment advice.

Eli Lilly shares fell approximately 2% following the release of mixed weekly prescription data for its GLP-1 drug portfolio. IQVIA data cited by Morgan Stanley showed Mounjaro total prescriptions rose to ~758,400 for the week ending April 17, 2026, up from ~749,500 the prior week, with new prescriptions also ticking higher to ~367,900. Despite the sequential growth in Mounjaro volumes, the broader mixed trends across the GLP-1 portfolio weighed on the stock.

AI-generated content for informational purposes only. Not investment advice.

Eli Lilly's new oral weight-loss drug Foundayo is showing slow early prescription uptake, according to new prescription data. The sluggish start highlights the challenge Lilly faces in competing with Novo Nordisk in the obesity drug market. The data represents an early indicator only and does not reflect long-term commercial trajectory.

AI-generated content for informational purposes only. Not investment advice.

CNBC highlights stocks with the largest midday price moves, including Intel, AMD, Charter, Hims & Hers, and Eli Lilly, among others. The article serves as a market roundup without providing specific details on the direction or magnitude of each move. No individual company news or catalysts are elaborated upon in the available text.

AI-generated content for informational purposes only. Not investment advice.

Eli Lilly shares fell as its obesity drug Foundayo showed a weaker early commercial trajectory compared to oral Wegovy, while Novo Nordisk shares climbed on the contrast. Regeneron announced a drug pricing deal, and two unspecified companies disclosed leadership changes. The FDA also announced plans to issue vouchers related to psychedelic treatments.

AI-generated content for informational purposes only. Not investment advice.

Hims & Hers Health is pivoting away from GLP-1 compounding, announcing it will allow providers to prescribe scripts filled through LillyDirect, Eli Lilly's direct-to-consumer platform. The move marks a strategic retreat from compounded GLP-1 drugs, which had been a key growth driver for the company. The stock is falling on the news, as the so-called "Netflix" argument — that Hims could build a subscription-based weight-loss platform — loses credibility.

AI-generated content for informational purposes only. Not investment advice.

Hims & Hers Health announced it will allow providers on its platform to prescribe medications fulfilled through LillyDirect, Eli Lilly's direct-to-consumer pharmacy service. The deal signals a shift in Hims & Hers' business model toward partnering with branded drug manufacturers rather than competing solely on compounded or generic alternatives. Hims stock dropped on the news, likely reflecting concerns about margin pressure or competitive dynamics.

AI-generated content for informational purposes only. Not investment advice.

The Motley Fool publishes a promotional piece advocating for the Vanguard S&P 500 ETF (VOO) as a long-term, low-cost investment vehicle. The article highlights the S&P 500's historical resilience across market crises and its index reconstitution mechanism as key advantages over active trading. Several S&P 500 constituent stocks — including AMZN, GOOG/GOOGL, MSFT, V, MA, LLY, and PLTR — are cited as examples of the index's holdings.

AI-generated content for informational purposes only. Not investment advice.